January 16, 2025
FRONTEO’s Drug Discovery AI Factory, an AI drug discovery service using unique technologies that discover unreported relationships from published literature, to support target identification and drug repositioning etc.
January 9, 2025
Accelerate indication identification and early licensing with FRONTEO’s unique technologies that systematically discovers unreported relationships between diseases and molecules from existing literature information.
November 14, 2024
Accelerate indication identification and early licensing with FRONTEO’s unique technologies that systematically discovers unreported relationships between diseases and molecules from existing literature information.
November 12, 2024
FRONTEO, Inc. (Head Office: Minato-ku, Tokyo; President and CEO: Masahiro Morimoto; hereafter "FRONTEO") is pleased to announce that an agreement has been reached to provide Daiichi Sankyo Co., Ltd. (Head Office: Chuo-ku, Tokyo; President and COO: Hiroyuki Okuzawa; hereafter "Daiichi Sankyo") with analysis services using Drug Discovery AI Factory (hereafter "DDAIF")* to analyze text information from toxicity study databases and reports.
May 13, 2024
FRONTEO, Inc. (Head Office: Tokyo, Japan; Chief Executive Officer: Masahiro Morimoto; hereafter "FRONTEO"), Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi; hereafter "Shionogi"), and Suzuken Co., Ltd. (Head Office: Nagoya, Japan; President and CEO: Shigeru Asano; hereafter "Suzuken") are pleased to announce that we will collaborate with the aim of implementing the conversational dementia diagnosis support AI program in society.
February 29, 2024
FRONTEO, Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Masahiro Morimoto) is hosting a free seminar “Recent Developments in AI and Competition Law – a Global Perspective” in collaboration with White & Case LLP on March 19th.
February 15, 2024
Tokyo, Japan, February 14, 2024 – FRONTEO, Inc. (Head Office: Tokyo, Japan; Chief Executive Officer: Masahiro Morimoto; hereafter "FRONTEO") and Shionogi Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi; hereafter "Shionogi") are pleased to announce that we have entered into a strategic business partnership agreement for the dementia-related AI program and depression-related AI program.
February 6, 2024
Enhanced function of the Drug Discovery AI Factory, analyze cutting-edge academic articles to propose highly novel target molecules and hypotheses
January 24, 2024
Explanation of points to keep in mind when Japanese companies negotiate with U.S. government agencies, crisis management, and the use of AI
January 12, 2024
FRONTEO is a proud sponsor of Legalweek 2024 at the New York Hilton Midtown – January 29th – February 1st. Come join your peers in the legal profession at this annual gathering.